search
Back to results

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty (FemVsACB)

Primary Purpose

Pain, Postoperative, Total Knee Arthroplasty (TKA)

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Continuous Femoral Nerve Block
Nerve Block, Continuous Adductor Canal
Continuous Sciatic Nerve Block
Bupivacaine
Sponsored by
Kevin King, DO
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Continuous Femoral Nerve Block, Continuous Adductor Canal Block

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Able to consent to regional anesthesia and having primary total knee arthroplasty/replacement

Exclusion Criteria:

  • Body-Mass Index >40
  • Iliac to Patella Distance (IPD) <40cm
  • Pre-existing quadriceps weakness of involved surgical side Chronic opioid use (if using opioids within 4 weeks of surgery: excluded)

Sites / Locations

  • University of Pittsburgh Medical Center - Passavant Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Cont. Femoral Block - Low Dose Group

Cont. Femoral Block - Higher Dose

Continuous Adductor Canal

Arm Description

Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.

Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy

Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.

Outcomes

Primary Outcome Measures

Time to Achieve Physical Therapy Discharge Criteria as Measured by 75-feet Walk Test. {Number of Hours After Conclusion of Surgery}
Ability to walk 75 feet if performed on POD#2 is usually considered the main criterion for discharge at UPMC Passavant. The patient is accompanied/supervised by physical therapist using a walker but without active intervention by therapist, unless necessary. The earliest day on which the patient achieves the 75-feet unassisted walk will be recorded for comparison among the arms/groups.

Secondary Outcome Measures

Average Length of Stay (to be Reported in Hours After Surgery)
If pain is controlled and rehabilitation activity is optimal patient may be discharged at an earlier time
Postoperative Pain, Average Reported Score 11-point Scale
The outcome is measured using a Numeric pain scale. The patient reports their average pain felt on postoperative day one, on a scale of 0 to 10 inclusive. Zero in this case indicates no pain at all and 10 indicates the worst pain they have ever felt.
Sustained Straight Leg Raise
Sustained Straight Leg Raise is the ability to elevate the heel and leg/knee off of bed for 5 seconds postoperatively after spinal anesthetic has resolved contralaterally.

Full Information

First Posted
April 24, 2015
Last Updated
February 27, 2018
Sponsor
Kevin King, DO
search

1. Study Identification

Unique Protocol Identification Number
NCT02453321
Brief Title
Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty
Acronym
FemVsACB
Official Title
A Comparison Between Continuous Selective Femoral Blocks and Continuous Adductor Canal Blocks at Mid-Thigh in Total Knee Arthroplasty: What is the Best Method to Optimize Functional Achievement and Analgesia in Early Rehabilitation?
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
June 2015 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
August 31, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kevin King, DO

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Recently, several articles have suggested or reported that Adductor Canal Blocks (ACBs) offer adequate or equal analgesia and may promote better performance in early rehabilitation following Total Knee Arthroplasty (TKA) when compared to the more commonly used Femoral Nerve Block (FNB). A common feature of these studies has been the use of moderate to high concentration local anesthetics (e.g. 0.2% or 0.5% Ropivacaine respectively) which when injected by a large motor nerve will inevitably cause weakness. However, the practice at our institution has long been a continuous femoral nerve block (CFNB) with a lower concentration local anesthetic (0.0625% Bupivacaine). Over the past several years the investigators have performed several thousand CFNBs using this technique which has offered the advantage of minimal motor weakness and adequate analgesia. The primary goal of this study is to determine if our established practice of using a low concentration continuous FNB inserted about 5cm caudal to the groin crease (the apex of the femoral triangle) using a low infusion rate of 2ml/hr is comparable to the emerging practice of inserting a Continuous Peripheral Nerve Block (CPNB) in the anatomic adductor canal (AC) - infusing at 4ml/hr. A secondary goal is to study the effect of cumulative volume of local anesthetic infused through a FNB when at a rate of 2ml/hr compared to a rate of 4ml/hr in the 48-hour postoperative period. Definitions of the location of the adductor canal are debated heavily in literature, but they seem to agree that the middle 1/3 of the thigh contains the proximal AC while the distal 1/3 of the thigh contains the adductor hiatus - the terminal end of the AC. Our study will require placement of the continuous ACB no more distal than 20cm cephalad to the superior pole of the patella due to placement prior to surgery and the need to keep the dressing out of the operative field. The CACB catheter will also not be placed any more proximal than 20cm distal to the ASIS. In addition to other exclusion criteria, these measurements will create an exclusion for patients with an iliac-to-patella distance less than 40cm. Iliac to Patella distance (IPD) will be measured at the pre-operative interview on the day of surgery with a measuring tape. External palpable landmarks of the Anterior superior iliac spine and the superior pole of the patella will be used. The primary outcome is based upon the ability to perform rehabilitation exercises postoperatively to the extent that criteria for discharge can be met. The primary outcome measured is the time at which a patient gains the ability to successfully perform a 75-feet unassisted walk. On the Day of Surgery (DOS), prior to any walking attempt, a secondary outcome measure will be to perform a 5-second sustained straight leg raise. Other secondary outcomes will be the number of days admitted prior to discharge, and average pain scores on DOS, Postoperative Day (POD) #1, and POD#2. The Day of discharge will also be used as a secondary outcome. Earlier discharge is becoming a goal of almost all healthcare systems to minimize costs.
Detailed Description
The three arms are as follows: The control group; Continuous Femoral Nerve Block - Low Dose (CFNB-LD) will be patients randomized to our standard therapy comprised of a low dose/concentration Continuous Femoral Nerve Block inserted approximately 5cm distal to the groin crease with a rate of 2ml/hr. Higher dose (HD) CFNB; - block placed in same location as CFNB-LD but with a higher dose rate of 4ml/hr. This higher rate could afford more pain control but may cause more quadriceps or hip flexor weakness. Continuous Adductor Canal Block (CACB) group will have a catheter inserted 20-30cm proximal to the superior pole of the patella, and an infusion rate of 4ml/hr, but with similar dressing to make it appear like those in group 1 and 2. Acute Pain/Regional anesthesiologists and fellows will be performing all research procedures in the same locations that the investigators routinely perform regional nerve blocks: our preoperative holding area adjacent to the operating room suites at University of Pittsburgh Medical Center (UPMC) - Passavant. All three groups have a set rate that will not increase. There also will be no bolus orders given on the floors, however IV and PO medications will be available to decrease discomfort. These medications are ordered to be given upon request (PRN); upon patient request. Down-regulation of doses will also not be allowed as that would cause uncertainty as to which regimen may contribute most to postoperative weakness. The only adjustment allowed will be to turn off the nerve block infusion completely on POD #1 if a dense motor block of the quadriceps or iliopsoas (hip flexor) exists, as this condition does not facilitate participation in rehabilitation exercises. The frequency of early-removal of nerve block will be recorded for all three groups. CFNB groups Continuous Femoral Nerve Block placement: The skin of the right or left groin will be sterilized and draped under sterile conditions, the femoral nerve will be identified using ultrasound just below the inguinal crease and the local anesthetic will be infiltrated subcutaneously. The needle is inserted at the lateral edge of the probe and directed toward the nerve using ultrasound assistance. When in proximity of the nerve, 15ml of 0.2% ropivacaine will be injected through the needle with repeat aspiration every 5 ml. The nerve block catheter will be placed 3-5 cm past the needle tip and secured with steri strips and bio-occlusive dressing. CACB group Continuous Adductor Canal Block placement: The distance from the ASIS to the superior pole of the patella will be measured and the distance recorded. This Iliac-to-Patella distance (IPD) will be divided into proximal and distal halves, and the halfway point marked. The length of the IPD will need to be a minimum of 40cm for inclusion. The insertion site will need to be 20cm proximal to the superior pole of the patella and at least 20ml distal to the ASIS. The attending anesthesiologist / acute pain attending either perform or supervise regional anesthesia fellows to place the CACB no more proximal than the halfway mark of the IPD. For example, if a patient has an IPD of 50cm, the halfway mark will be at 25cm and this would be the site of insertion as it would be within the anatomic adductor canal and would be adequately removed from the surgical site. The skin of the right or left anterior-medial thigh will be sterilized and draped under sterile conditions. The sartorius muscle and femoral artery will be identified by an ultrasound at the marked IPD-halfway-mark. There, local anesthetic will be infiltrated subcutaneously. The needle is inserted in the direction of the hyperechoic nerve and the hypoechoic femoral artery using ultrasound assistance. When the needle tip is deep to the sartorius and in proximity of the artery, 15ml of 0.2% ropivacaine will be injected through the needle with repeat aspiration every 5 ml. The nerve catheter will be placed 3-5 cm past the needle tip and secured with steri-strips and bio-occlusive dressing. The CACB rate will be 4ml/hr of bupivacaine 0.0625%. By design, Observers should only be aware of a singular kind of patient; those with CPNBs. The dressing of the cACB will be very similar to the CFNB and the standard yellow connector piece will be secured to the skin with bio-occlusive covering, and the location will be at level of the anterior superior iliac spine (ASIS). This standardized dressing will serve to aid in blinding the observers as to which kind of continuous block the patient received. Labeling of the catheter and dressing will not differ. The nerve block billing record will contain the information on the particular approach used. Sciatic nerve block placement: the corresponding right or left gluteal area will be sterilized and draped under sterile conditions, the sciatic nerve will be identified by an ultrasound in the lower gluteal region where a local anesthetic will be infiltrated subcutaneously. A trans-gluteal approach will be used to inject normal saline through the needle to assist catheter placement; the catheter will be introduced for 3-5 cm past the needle tip and secured with steri strips and tegaderm. No local anesthetic will be administered until the postoperative period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Total Knee Arthroplasty (TKA)
Keywords
Continuous Femoral Nerve Block, Continuous Adductor Canal Block

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cont. Femoral Block - Low Dose Group
Arm Type
Active Comparator
Arm Description
Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
Arm Title
Cont. Femoral Block - Higher Dose
Arm Type
Experimental
Arm Description
Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
Arm Title
Continuous Adductor Canal
Arm Type
Experimental
Arm Description
Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
Intervention Type
Procedure
Intervention Name(s)
Continuous Femoral Nerve Block
Other Intervention Name(s)
Continuous Nerve Block, Femoral, Continuous Peripheral Nerve Block
Intervention Description
A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
Intervention Type
Procedure
Intervention Name(s)
Nerve Block, Continuous Adductor Canal
Other Intervention Name(s)
Continuous Nerve Block, Adductor Canal, Continuous Peripheral Nerve Block, Adductor Canal
Intervention Description
A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
Intervention Type
Procedure
Intervention Name(s)
Continuous Sciatic Nerve Block
Other Intervention Name(s)
Nerve Block, Sciatic Continuous
Intervention Description
A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
Primary Outcome Measure Information:
Title
Time to Achieve Physical Therapy Discharge Criteria as Measured by 75-feet Walk Test. {Number of Hours After Conclusion of Surgery}
Description
Ability to walk 75 feet if performed on POD#2 is usually considered the main criterion for discharge at UPMC Passavant. The patient is accompanied/supervised by physical therapist using a walker but without active intervention by therapist, unless necessary. The earliest day on which the patient achieves the 75-feet unassisted walk will be recorded for comparison among the arms/groups.
Time Frame
Participants will be followed for the duration of hospital stay, an average of 4 days
Secondary Outcome Measure Information:
Title
Average Length of Stay (to be Reported in Hours After Surgery)
Description
If pain is controlled and rehabilitation activity is optimal patient may be discharged at an earlier time
Time Frame
Participants will be followed for the duration of hospital stay; No patients will be discharged on the day of surgery; The earliest discharge would be at 24 hours. Those hospitalized beyond 96 hours will be excluded.
Title
Postoperative Pain, Average Reported Score 11-point Scale
Description
The outcome is measured using a Numeric pain scale. The patient reports their average pain felt on postoperative day one, on a scale of 0 to 10 inclusive. Zero in this case indicates no pain at all and 10 indicates the worst pain they have ever felt.
Time Frame
postoperative day one
Title
Sustained Straight Leg Raise
Description
Sustained Straight Leg Raise is the ability to elevate the heel and leg/knee off of bed for 5 seconds postoperatively after spinal anesthetic has resolved contralaterally.
Time Frame
Day of Surgery (DOS) - In Postoperative Recovery Unit, prior to any walking atempt

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Able to consent to regional anesthesia and having primary total knee arthroplasty/replacement Exclusion Criteria: Body-Mass Index >40 Iliac to Patella Distance (IPD) <40cm Pre-existing quadriceps weakness of involved surgical side Chronic opioid use (if using opioids within 4 weeks of surgery: excluded)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Waters Jonathan, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Study Chair
Facility Information:
Facility Name
University of Pittsburgh Medical Center - Passavant Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15237
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

We'll reach out to this number within 24 hrs